Multiple sclerosis (MS) is a wolf in sheep's clothing. While such an assertion may attract some controversy, there is little argument that therapeutic strategies for MS have focussed almost entirely on inflammatory aspects of the disease and largely disregarded the lupine menace of neurodegeneration, despite its robust association with disability. The recent advent of antiinflammatory medicines that all but eradicate the formation of new MS lesions heralds a critical juncture in therapeutics research that should signal both researchers and the pharmaceutical industry to regroup, reprioritise and invest in the discovery of targets relevant to neuroprotection and neuro-repair. The event(s) that incites MS has not been definitively characterised. While histopathological, immunological and genetic studies support immune system dysregulation as a key patho-mechanism for MS, the prima facie argument for inflammation as the initial pathophysiological event has not been proven; and studies observing oligodendrocyte apoptosis in nascent, pre-phagocytic MS lesions; 1 and the induction of inflammation by primary oligodendrocyte deficits in animal models, 2 hint at a more fundamental, and as yet, unexplored neurobiological process.
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The prevailing view that MS is an inflammatory disease of the white matter has driven the evolution of MS therapeutics. This approach has yielded remarkable advances in our understanding of the molecular pathogenesis of inflammation in MS, generating a raft of highly efficacious therapies and transforming the lives of patients with aggressive, relapsing disease phenotypes. However, the absence of a specific 'MS antigen' has necessarily impeded the development of targeted immunotherapies that lack the unwanted, broader immunosuppressive effects typical of modern MS disease-modifying therapies (DMTs). It seems unlikely that further efficacy gains will be realised in this class of medications; rather, future developments will primarily focus on reducing adverse events and improving the burden of treatments, both to patients and to neurologists.
Critically, prominent neurodegenerative processes including neuro-axonal loss and synaptic loss are evident at the earliest stages of disease and constitute the dominant pathology and key drivers of disability accrual during the natural course of later disease. Trapp et al.'s 3 demonstration of massive axonal injury within acute MS plaques, itself a recapitulation of early histopathological studies, highlighted the importance of axonal injury and refocussed the attention of MS trialists on disability outcomes. Subsequent research has identified lesion-related Wallerian, retrograde and even trans-synaptic neurodegeneration as probable contributors to brain atrophy, the magnetic resonance imaging (MRI) correlate that best associates with disability progression. 4 MRI evidence of progressive axonal loss in the core of chronic MS lesions 5 and persistently accelerated brain atrophy in otherwise quiescent disease speaks to a critical unmet therapeutic need in MS.
Demyelination, which deprives axons of metabolic and trophic support, and leads to redistribution of axonal voltage-gated Na + channels, contributes to increased energy demands and a state of virtual hypoxia that ultimately results in neurodegeneration. Additional key patho-mechanisms that drive neuro-axonal injury in MS include mitochondrial injury related to prolonged oxidative stress, axonal transport defects and brain iron accumulation. 6 While inflammatory-dependent and inflammatory-independent processes play a role in each of these mechanisms, their direct targeting will likely limit neurodegeneration.
Immune-directed DMTs now come in a variety of mechanistic flavours, from immunomodulatory agents such as beta-interferon and glatiramer acetate through to potent monoclonal antibody immune-cell depleting therapies such as alemtuzumab 
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JY Garber and MH Barnett and ocrelizumab. Relapse rates on the most effective anti-inflammatory treatments are vanishingly low, MRI activity is rare and yearly brain atrophy rates may return to within the normal range. Although yet to be proven, immune therapy is also likely to delay onset of secondary progression. Despite these successes, immune therapies do not appear to prevent gradual attrition of axons within established MS lesions, 5 the likely pathological correlate of relapseindependent disability worsening, and do not significantly impact long-term neurodegeneration in progressive forms of MS without superimposed clinical or radiological disease activity. This group of patients has therefore been relegated to a largely treatment-free zone; and only recently have researchers, and research funders, begun to take greater interest in their plight, most notably with the formation of the International Progressive MS Alliance.
There are promising beginnings. Potential targets of neurodegenerative mechanisms such as energy failure, free radical production and excitotoxicity have been identified. 7 Pro-remyelinating agents, the first to specifically target repair in MS, are of particular interest. Opicinumab, a monoclonal antibody targeting LINGO1, a central nervous system (CNS)-specific membrane glycoprotein that suppresses oligodendrocyte differentiation and myelination, is the first 'cab off the rank' in this treatment class. Having shown significant remyelinating potential in animal models of demyelination, opicinumab was trialled in the RENEW study of patients with acute optic neuritis. 8 An improvement in visual evoked potential latency in the treatment arm confirmed an effect on remyelination, and while lack of an effect on the retinal ganglion cell (RGC) fibre layer thickness might imply the absence of a neuroprotective benefit, it is likely that loss of RGCs reflected the effects of axonal transection in the acute lesion that had taken place prior to administration of study drug. By preventing or reducing the gradual attrition of susceptible, denuded axons associated with longer term disability accrual, the clinical benefits of opicinumab and other pro-remyelinating agents may only be realised over the longer term, emphasising the importance of developing robust, in vivo biomarkers of remyelination for future clinical trials.
MS researchers are heeding the call to focus on remyelinating therapies with several multicentre collaborations creating high-throughput drug discovery sequences in the field. Such a collaboration unmasked the remyelinating potential of clemastine fumarate, a first-generation antihistamine that enhances oligodendrocyte differentiation without affecting inflammation.
Promising effects on chronic demyelinating injury have already been reported. 9 Finally, high-dose biotin is now the focus of a large randomised control trial in progressive MS following a positive impact on disability outcomes in a smaller, Phase 2 study. Biotin may have both an effect on myelin repair, through activation of carboxylases, and neuroprotection, by supporting mitochondrial energy production. 10 These therapeutic advances, which target non-inflammatory damage, have been made despite a comparatively small research effort and limited resource expenditure. They provide the MS community with bright hope that a more concentrated focus on these mechanisms will bring about real change in the management of MS, particularly in prevention and treatment of progressive disease. Ultimately, we foresee a multimodal treatment strategy, in which neuroprotective and remyelinating therapies stand shoulder to shoulder with immune-directed DMTs, to keep the wolf at bay and prevent disability accrual in MS.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. 
